MedinCell S.A.
MEDCL.PA · PAR
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | €25,541 | €9,160 | €9,944 | €4,090 |
| % Growth | 178.8% | -7.9% | 143.1% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €25,541 | €9,160 | €9,944 | €4,090 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | €24,313 | €21,076 | €27,925 | €23,607 |
| G&A Expenses | €0 | €9,153 | €7,128 | €6,214 |
| SG&A Expenses | €529 | €11,792 | €9,716 | €8,486 |
| Sales & Mktg Exp. | €529 | €2,639 | €2,588 | €2,272 |
| Other Operating Expenses | €11,539 | -€2,337 | €0 | €0 |
| Operating Expenses | €36,381 | €30,137 | €33,989 | €27,904 |
| Operating Income | -€10,840 | -€20,977 | -€24,025 | -€23,814 |
| % Margin | -42.4% | -229% | -241.6% | -582.2% |
| Other Income/Exp. Net | -€7,438 | -€3,973 | -€7,964 | -€994 |
| Pre-Tax Income | -€18,278 | -€24,950 | -€32,010 | -€24,806 |
| Tax Expense | €160 | €88 | €0 | €0 |
| Net Income | -€18,438 | -€25,038 | -€32,010 | -€24,806 |
| % Margin | -72.2% | -273.3% | -321.9% | -606.5% |
| EPS | -0.63 | -0.88 | -1.27 | -1 |
| % Growth | 28.4% | 30.7% | -27% | – |
| EPS Diluted | -0.63 | -0.88 | -1.27 | -1 |
| Weighted Avg Shares Out | 29,101 | 28,420 | 25,188 | 24,865 |
| Weighted Avg Shares Out Dil | 29,101 | 28,420 | 25,188 | 24,865 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | -€44 | €1 | €46 |
| Interest Expense | €5,088 | €4,617 | €3,932 | €1,844 |
| Depreciation & Amortization | €1,990 | €1,719 | €1,665 | €1,516 |
| EBITDA | -€11,200 | -€18,614 | -€26,413 | -€21,446 |
| % Margin | -43.9% | -203.2% | -265.6% | -524.4% |